Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein,Clinical Infectious Diseases

当前位置： X-MOL 学术 › Clin. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
Clinical Infectious Diseases ( IF 8.2 ) Pub Date : 2020-01-04 , DOI: 10.1093/cid/ciz1239
Mina C Hosseinipour _{1,

2} , Craig Innes ₃ , Sarita Naidoo ₄ , Philipp Mann ₅ , Julia Hutter ₆ , Gita Ramjee ₄ , Modulakgotla Sebe ₇ , Lucas Maganga ₈ , Michael E Herce ₉ , Allan C deCamp ₅ , Kyle Marshall ₅ , One Dintwe _{5,

10} , Erica Andersen-Nissen _{5,

10} , Georgia D Tomaras ₁₁ , Nonhlanhla Mkhize ₁₂ , Lynn Morris ₁₂ , Ryan Jensen ₅ , Maurine D Miner ₅ , Giuseppe Pantaleo ₁₃ , Song Ding ₁₄ , Olivier Van Der Meeren ₁₅ , Susan W Barnett ₁₆ , M Juliana McElrath ₅ , Lawrence Corey ₅ , James G Kublin ₅ ,

Affiliation

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC Project-Malawi, Lilongwe, Malawi.
Aurum Institute, Klerksdorp, South Africa.
HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Aurum Institute, Tembisa, South Africa.
NIMR-Mbeya Medical Research Center, Mbeya, Tanzania.
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Cape Town HVTN Immunology Laboratory, Cape Town, South Africa.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
EuroVacc Foundation, Lausanne, Switzerland.
GSK Vaccines, Rixensart, Belgium.
GSK Vaccines, Cambridge, Massachusetts, USA.

The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different adjuvants and priming agents for human immunodeficiency virus (HIV) type 1 (HIV-1) prevention.

中文翻译：

用于评估 HIV C 亚型 DNA 和 MF59 佐剂 C 亚型包膜蛋白的安全性和免疫原性的人类免疫缺陷病毒 (HIV) 疫苗试验 1 期

Pox-Protein Public-Private Partnership 正在进行一系列试验，以在人类免疫缺陷病毒 (HIV) 的不同佐剂和引发剂的背景下评估二价 C 亚型包膜蛋白（TV1.C 和 1086.C 糖蛋白 120）疫苗1 型 (HIV-1) 预防。

更新日期：2020-01-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>